Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 131.0 | 63 | |
RA2159 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 12033.5 | 56 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 46.0 | 58 | |
N2645 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 76.0 | 53 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 1400.5 | 74 | |
RA2708 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 12742.0 | 53 | |
RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 16910.0 | 50 | |
RA2159 | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 18507.0 | 61 | ||||
N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 543.0 | 69 | |
N2645 | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 4757.5 | 46 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 18758.0 | 48 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 4 | GRO-a | 17834.0 | 40 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 232.5 | 58 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 13063.0 | 52 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 412.5 | 52 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 5422.0 | 57 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 1874.5 | 58 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 19043.5 | 50 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 18827.0 | 57 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 18997.5 | 40 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 16444.0 | 45 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 16738.5 | 50 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 17503.0 | 51 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | GRO-a | 18575.0 | 43 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | GRO-a | 987.0 | 51 |